Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check7 days agoChange Detected- The page revision has been updated to v3.6.5. The previous revision indicator v3.6.4 has been replaced.SummaryDifference0.0%

- Check14 days agoChange DetectedThe study record now includes new registry identifiers (UTN and EU CT) and adds data-sharing resources: a PDF with data-access procedures and an external data-sharing site, while older EngageZone links were removed. These changes place the trial's data-sharing framework and identifiers into current reference points for researchers and stakeholders.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a new build of the underlying documentation/system. This change is an internal version update rather than a visible content update.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedRevision: v3.6.3 was added and Revision: v3.6.2 was removed. This indicates the page's revision history has been updated.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision label changed from v3.6.0 to v3.6.2, indicating a patch-level update to the page. This update does not alter study content or results.SummaryDifference0.0%

- Check64 days agoChange DetectedA recruitment-status indicator was added, signaling that the study is no longer recruiting participants. Additionally, new navigation/help items were added, the Interventions header formatting was standardized to Intervention/Treatment, and the revision tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.